Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats

Table 3

Pharmacokinetic parameters of MDZ (10 mg/kg, i.v.) after treatment with baicalin.

	Control	Baicalin (0.90 g/kg, 1 day)		Baicalin (0.90 g/kg, 7 days)
	Value	Value	Ratio	Value	Ratio
𝐶max (mg/L)	6.3±1.3	7.0±1.2	1.13 (0.92 ∼ 1.34)	7.8±0.9^∗	1.27 (1.03 ∼ 1.51)
𝑡1/2 (h)	0.40±0.10	0.47±0.11		0.44±0.10
𝑉 (L/kg)	3.2±0.9	2.5±0.5		1.9±0.4^∗∗
CL (L/h/kg)	5.6±0.7	3.7±0.6^∗∗∗	0.66 (0.58 ∼ 0.74)	3.2±0.8^∗∗∗	0.57 (0.43 ∼ 0.71)
AUC0--𝑡 (mg·h/L)	1.7±0.2	2.6±0.4^∗∗	1.50 (1.34 ∼ 1.67)	3.2±0.8^∗∗	1.86 (1.48 ∼ 2.24)
AUC0--∞ (mg·h/L)	1.8±0.2	2.8±0.5^∗∗	1.53 (1.34 ∼ 1.73)	3.4±0.9^∗∗	1.87 (1.47 ∼ 2.28)

Rats received intravenous administration of baicalin at a dose of 0.90 g/kg once for 1 day and the same dose for 7 days. The results are means ± SD of 8 rats. Ratios are expressed as geometric mean ratio with 90% CI. Significance is indicated as *P < 0.05; **P < 0.01; ***P < 0.001 compared to the control.